Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan

Mizumachi, Takatsugu; Homma, Akihiro; Sakashita, Tomohiro; Kano, Satoshi; Hatakeyama, Hiromitsu; Fukuda, Satoshi

Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan

Mizumachi, Takatsugu; Homma, Akihiro; Sakashita, Tomohiro et al.

International journal of clinical oncology, 2017, 22(4), 682-689

Permalink : https://hdl.handle.net/2115/71138

このアイテムのアクセス数:1,100件（2026-08-13 10:16 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
IntJClinOncol22_682	pdf	277 KB	1,065

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/71138
タイトル	Confirmation of the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan
その他のタイトル	Confirmation of the 8th edition of the AJCC/UICC TNM staging system for HPV-mediated oropharyngeal cancer in Japan
著者	Mizumachi, Takatsugu ; Homma, Akihiro ; Sakashita, Tomohiro ; Kano, Satoshi ; Hatakeyama, Hiromitsu ; Fukuda, Satoshi
e-Rad_Researcher 00507577 著者名 Mizumachi, Takatsugu
e-Rad_Researcher 30312359 著者名 Homma, Akihiro
e-Rad_Researcher 30455654 著者名 Sakashita, Tomohiro
e-Rad_Researcher 00374421 著者名 Kano, Satoshi
e-Rad_Researcher 10455652 著者名 Hatakeyama, Hiromitsu
e-Rad_Researcher 20125347 著者名 Fukuda, Satoshi
言語	英語
キーワード	AJCC/UICC TNM staging system
	Head and neck cancer
	Human papillomavirus
	Oropharynx
	p16
発行日	2017-08
出版者	Springer
収録物名	International journal of clinical oncology
巻(号)	22(4)
ページ	682-689
抄録	Background: Several studies have demonstrated that the 7th edition of the AJCC/UICC TNM staging classification system does not consistently distinguish between prognostic subgroups for human papillomavirus (HPV)-mediated oropharyngeal squamous cell carcinoma (OPSCC). The 8th edition of the AJCC/UICC TNM staging came into effect for use with HPV-mediated OPSCC on or after January 1, 2017. This study confirms that the 8th edition of the AJCC/UICC TNM staging system for HPV- mediated OPSCC accurately reflects disease outcomes. Patients and methods:We retrospectively analyzed 195 patients with OPSCC treated at Hokkaido University Hospital, Sapporo, Japan between 1998 and 2015. HPV status was evaluated by immunohistochemical analysis of p16. Results: Of the 195 OPSCC patients, 111 (56.9%) were p16 positive, and 84 (43.1%) were p16 negative. The 3-year overall survival rate (OS) was significantly lower in the p16-negative patients with stage III-IV in comparison with those with stage I-II (55.0% vs 93.1%, p<0.01). The 3-year OS did not differ significantly between stage I-II and stage III-IV in the p16-positive patients (86.7% vs 87.7%). According to the 8th edition of the AJCC/UICC TNM staging system, stage I-II and stage III could be differentiated on the basis of the 3-year OS in the p16-positive patients (90.9% vs 70.2%, p<0.01). Conclusions: The 7th edition of the AJCC/UICC TNM staging system is suitable for use with p16-negative patients; however, it does not effectively discriminate between p16-positive patients. Therefore, the 8th edition of the AJCC/UICC TNM staging system is more suitable for HPV-mediated OPSCC in Japan.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	This is a post-peer-review, pre-copyedit version of an article published in International Journal of Clinical Oncology. The final authenticated version is available online at: http://dx.doi.org/10.1007/s10147-017-1107-0
PISSN	1341-9625
関連情報	PMID 28271391
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1007/s10147-017-1107-0